Home › Short Regeneron: Further Downside Ahead For This Bloated Large-Cap...
 

Keywords :   


Short Regeneron: Further Downside Ahead For This Bloated Large-Cap...

2016-03-07 18:44:11| Biotech - Topix.net

Regeneron reported disappointing full-year 2015 results in early February, and once booming sales of EYLEA are starting to finally exhibit some sluggishness. The company's heavily-anticipated PCSK9 drug, Praluent, launched in mid-2015, but has yet to exhibit sales that were expected from the potential billion-dollar rock star.

Tags: short ahead downside bloated

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
More »